Advances in the Management of Chemotherapy-Induced Neutropenia

Updates in the prevention and management of chemotherapy-induced neutropenia, specifically in breast cancer, with special considerations for the impact of new data on practice patterns.

EP. 1: Consequences of Chemotherapy-Induced Neutropenia

October 22nd 2021

A panel of breast oncologists define chemotherapy-induced neutropenia in terms of how they assess risk and attempt to prevent treatment-related toxicities in patients with cancer.

EP. 2: Guideline Recommendations for CIN Prophylaxis

October 22nd 2021

Current recommendations by the National Comprehensive Cancer Network on chemotherapy-induced neutropenia prophylaxis, with special considerations for managing patients with cancer during COVID-19.

EP. 3: CIN Prophylaxis: When to Intervene

October 22nd 2021

Variables that oncologists should consider when determining when to initiate prophylactic therapy for chemotherapy-induced neutropenia in patients with breast cancer.

EP. 4: G-CSFs for Chemotherapy-Induced Neutropenia

October 22nd 2021

Breast oncologists react to the availability of granulocyte colony-stimulating factors, used as prophylaxis against chemotherapy-induced neutropenia.

EP. 5: CIN Prophylaxis: Treating With G-CSFs

October 29th 2021

Advantages, in terms of safety and efficacy, of granulocyte colony-stimulating factors used as prophylaxis against chemotherapy-induced neutropenia.

EP. 6: Managing Chemotherapy-Induced Neutropenia With G-CSFs

October 29th 2021

Recommendations for intervening with growth factor support and important considerations for reducing or discontinuing anti-cancer therapy when patients show signs of neutropenia.

EP. 7: Managing CIN in Patients With Breast Cancer

November 5th 2021

Preventive therapies and factors that impact how to best mitigate chemotherapy-induced neutropenia in patients with breast cancer.

EP. 8: Anticancer Therapy: Safety vs Efficacy

November 5th 2021

Breast oncologists discuss how they weigh the efficacy of anticancer treatment with the possibility of a treatment-related adverse event, like chemotherapy-induced neutropenia.

EP. 9: CIN Prophylaxis and Bone Pain

November 12th 2021

Recommendations regarding how to best manage patients who experience bone pain from chemotherapy-induced neutropenia prophylaxis with growth factor support.

EP. 10: Potential Dosing Strategies to Mitigate CIN

November 12th 2021

Considerations regarding the potential to prevent chemotherapy-induced neutropenia with newer therapeutic strategies as well as changes to treatment dosages.

EP. 11: CIN Treatment Advances: SIMBA Therapy

November 12th 2021

What to know about plinabulin, a first-in-class selective immunomodulating microtubule-binding agent (SIMBA), in preventing chemotherapy-induced neutropenia.

EP. 12: CIN: Takeaways From the PROTECTIVE-1 Study

November 12th 2021

An overview of the design and results of the PROTECTIVE-1 study of plinabulin versus pegfilgrastim in patients with solid tumors receiving docetaxel myelosuppressive chemotherapy.

EP. 13: CIN: Implications of the PROTECTIVE-2 Study

November 29th 2021

Implications for treating patients with solid tumor cancers with plinabulin based on quality-of-life data and results demonstrated by the PROTECTIVE-2 trial.

EP. 14: Novel Chemoprotective Therapies Under Investigation

November 29th 2021

Novel agents under investigation to help address unmet needs in the field of prophylaxis against neutropenia and other toxicities associated with chemotherapies used to treat solid tumors.

EP. 15: CIN: Adopting SIMBA Therapy Into Clinical Practice

December 3rd 2021

A panel of oncologists react to their interest in using plinabulin as prophylaxis against chemotherapy-induced neutropenia in future clinical practice.

EP. 16: Therapeutic Advances in Prophylaxis Against CIN

December 3rd 2021

An overview of therapies used as prophylaxis against chemotherapy-induced neutropenia and projections on improving quality of life for patients with solid tumors with therapeutic advances.